Aldeyra Therapeutics, Inc. Logo

Aldeyra Therapeutics, Inc.

Biotech developing therapies for ocular and systemic immune-mediated inflammation.

ALDX | US

Overview

Corporate Details

ISIN(s):
US01438T1060
LEI:
Country:
United States of America
Address:
131 HARTWELL AVENUE, 2421 LEXINGTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing medicines to treat immune-mediated diseases. The company's portfolio of product candidates is designed to inhibit inflammatory cells associated with both ocular and systemic ailments, addressing unmet needs where existing treatments are insufficient. Through ongoing clinical trials, Aldeyra is advancing a pipeline of next-generation therapies with the objective of improving patient well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Aldeyra Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Aldeyra Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Aldeyra Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
MetaVia Inc. Logo
A clinical-stage biotech developing novel drugs for cardiometabolic diseases like obesity and MASH.
United States of America MTVA
Metsera, Inc. Logo
Develops potent, long-acting oral & injectable therapies for obesity & metabolic diseases.
United States of America MTSR
Mezzion Pharma Co., Ltd. Logo
Develops and out-licenses novel therapeutics like udenafil, with a focus on rare diseases.
South Korea 140410
MFC Co., Ltd. Logo
A GMP-certified CDMO/CMO developing and manufacturing APIs for the global pharma sector.
South Korea 432980
Milestone Pharmaceuticals Inc. Logo
Developing a self-administered nasal spray for at-home treatment of acute cardiac events.
United States of America MIST
MIMEDX GROUP, INC. Logo
Provides placental-based biologics for advanced wound care, surgical, and burn applications.
United States of America MDXG
Mind Medicine (MindMed) Inc. Logo
Developing psychedelic-inspired medicines and novel therapies for brain health disorders.
United States of America MNMD
Mineralys Therapeutics, Inc. Logo
Developing targeted treatments for hypertension & CKD driven by elevated aldosterone.
United States of America MLYS
MiNK Therapeutics, Inc. Logo
Developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases.
United States of America INKT
MIRA PHARMACEUTICALS, INC. Logo
Develops novel ketamine and THC analogs for neurologic and neuropsychiatric disorders.
United States of America MIRA

Talk to a Data Expert

Have a question? We'll get back to you promptly.